Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials.

Liang Shi,Zhe Liu,Junfang Tang,Li Tong

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials.

2013

Liang Shi
Zhe Liu
Junfang Tang
Li Tong

e19149 Background: Gefitinib and erlotinib are oral EGFR-TKIs widely used in advanced NSCLC. The reported incidence and risk of interstitial lung disease (ILD) events associated with gefitinib and ...

Keywords:

Pathology
Clinical trial
non small cell
Interstitial lung disease
Erlotinib
Lung cancer
Gefitinib
Internal medicine
Meta-analysis
Oncology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations